Go to
JCI Insight
Citations to this article
Alison C. West, Ricky W. Johnstone
Published January 2, 2014
Citation Information: J Clin Invest. 2014;124(1):30-39. https://doi.org/10.1172/JCI69738.
Citation Information: J Clin Invest. 2014;124(1):30-39. https://doi.org/10.1172/JCI69738.
Abstract
Epigenetic enzymes are often dysregulated in human tumors through mutation, altered expression, or inappropriate recruitment to certain loci. The identification of these enzymes and their partner proteins has driven the rapid development of small-molecule inhibitors that target the cancer epigenome. Herein, we discuss the influence of aberrantly regulated histone deacetylases (HDACs) in tumorigenesis. We examine HDAC inhibitors (HDACis) targeting class I, II, and IV HDACs that are currently under development for use as anticancer agents following the FDA approval of two HDACis, vorinostat and romidepsin.
Authors
Alison C. West, Ricky W. Johnstone
Total citations by year
Citation information
Citations to this article in year 2015 (61)
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)